Description of the medicine: Flushpirilen (Fluspirilenum)
FLUSHPIRYLENE (Fluspirilenum). 8- [4, 4-Bis- (para-fluorophenyl) -butyl] - 1-phenyl-1, 3, 8-triazaspiro [4, 5] decan-4-one.
Synonyms: Fluspirilen, Fluspirilene, Redeptin, Spirodiflamine, IMAP (intramuscular antipsychotic).
Microcrystalline powder, insoluble in water. It is produced as a suspension in water containing 0.002 g (2 mg) of the preparation in 1 ml.
Flushpirilen is a derivative of diphenylbutylpiperidine. It is an active antipsychotic agent that has a pronounced antipsychotic effect. The spectrum of pharmacological action is close to haloperidol. Effective in hallucinations, delirium, autism. It also calms emotional and psychomotor agitation.
The main feature of flushpirylene is its prolonged action. After a single intramuscular injection in the form of a suspension, the effect lasts for 1 week.
The drug is used primarily for maintenance treatment of patients suffering from chronic mental illness after treatment in a hospital. It is convenient for use in outpatient practice due to the lack of pronounced hypnosative effects. Facilitates readaptation and rehabilitation of patients. Flushpirilen can also be used in a hospital with schizophrenia and other mental illnesses, accompanied by hallucinations, delusions, and psychomotor agitation. Flushpirilen can be combined with conventional (non-prolonged) antipsychotic drugs that have a psycho-sedative effect.
A flushpirylene suspension is administered intramuscularly once a week. In a hospital setting, 4–6 mg (2–3 ml) is first administered, and if necessary, the dose is increased to 8–10 mg (4–5 ml). Upon reaching the optimal effect, the dose is gradually reduced to a maintenance weekly dose of 2-6 mg (1-3 ml).
With prolonged treatment, you can take a weekly break every 3 to 4 weeks.
On an outpatient basis, 2-6 mg (1-3 ml) are administered once a week.
When using the drug, extrapyramidal disorders may develop; to prevent them, it is recommended that antiparkinsonian drugs be used on the day of flushpirylene administration and in the next 2 days. With prolonged treatment with flushpirylene, weight loss, general weakness, sleep impairment, depression are possible. On the first day after the injection, nausea and a feeling of fatigue may occur.
The drug is contraindicated in extrapyramidal disorders, depression, motor disorders.
Flushpirilen should not be prescribed to women in the first 3 months of pregnancy.
Release form: in 2 ml ampoules with the content in 1 ml of 0.002 g (2 mg) of flushpirylene (4 mg in 1 ampoule). Before injection, the vial should be shaken vigorously (to homogenize the suspension).